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Introduction: We have identified structural determinants on tau protein that are essential for pathological
tau–tau interaction in Alzheimer’s disease (AD). These regulatory domains, revealed by monoclonal antibody DC8E8,
represent a novel target for tau-directed therapy. In order to validate this target, we have developed an active
vaccine, AADvac1.
Methods: A tau peptide encompassing the epitope revealed by DC8E8 was selected for the development of an
active vaccine targeting structural determinants on mis-disordered tau protein that are essential for pathological
tau–tau interaction. The efficacy of the vaccine was tested in a transgenic rat model of human tauopathies.
Toxicology and safety pharmacology studies were conducted under good laboratory practice conditions in multiple
rodent and nonrodent species.
Results: We have administered the tau peptide vaccine to a rat model of AD to investigate whether the vaccine
can improve its clinical, histopathological and biochemical AD phenotype. Our results show that vaccination
induced a robust protective humoral immune response, with antibodies discriminating between pathological and
physiological tau. Active immunotherapy reduced the levels of tau oligomers and the extent of neurofibrillary
pathology in the brains of transgenic rats. Strikingly, immunotherapy has reduced AD-type hyperphosphorylation of
tau by approximately 95%. Also, the tau peptide vaccine improved the clinical phenotype of transgenic animals.
Toxicology and safety pharmacology studies showed an excellent safety and tolerability profile of the AADvac1
vaccine.
Conclusions: Active immunisation targeting crucial domains of Alzheimer tau eliminated tau aggregation and
neurofibrillary pathology. Most importantly, the AD type of tau hyperphosphorylation was abolished by vaccination
across a wide range of AD phospho-epitopes. Our results demonstrate that active immunisation led to elimination
of all major hallmarks of neurofibrillary pathology, which was reflected by a profound improvement in the clinical
presentation of transgenic rats. This makes the investigated tau peptide vaccine a highly promising candidate
therapeutic for the disease-modifying treatment of AD. The tested vaccine displayed a highly favourable safety
profile in preclinical toxicity studies, which opens up the possibility of using it for AD prophylaxis in the future. The
vaccine has already entered phase I clinical trial under the name AADvac1.
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Over the course of Alzheimer’s disease (AD), neurofibril-
lary pathology spreads through the human brain, grad-
ually disabling affected regions and leading to a decline
in cognitive function. The spatial distribution and sever-
ity of neurofibrillary lesions closely correlates with cog-
nitive impairment and brain atrophy observed in AD
[1-3]. With no effective therapy available and the con-
tinuing aging of the population, the number of patients
is rising quickly. More than 30 million people in the
world today are affected by dementia, and it is predicted
that the number of patients will reach over 100 million
by 2050 [4]. Current pharmacological treatment of AD is
based on the use of acetylcholinesterase inhibitors that
are able to produce moderate symptomatic benefits for
over 12 months [5]. However, they could not halt disease
progression. It is important to note that no new drug
against AD has been marketed for almost 17 years.
Therefore, there is a huge demand for the development
of disease-modifying drugs for AD that could attenuate
or even reverse the neurodegenerative process by target-
ing a major hallmark of the disease, such as neurofibril-
lary degeneration.
The concept of immunotherapy has gained a strong
foothold in the AD field [6]. Up to now, several ap-
proaches to immunotherapy have been tested in clinical
studies with the aim to counteract amyloid pathology and
thus improve cognition [7]. Despite the fact that active
and passive immunisation against amyloid-β (Aβ) has
been shown to clear or prevent Aβ brain plaques and im-
prove cognitive performance in numerous mouse model
studies [8], large-scale trials of several immunotherapeu-
tics targeting Aβ have displayed little or no cognitive effi-
cacy [6]. Therefore, much attention is now directed to
immunotherapy targeting tau protein [9-12]. Several inde-
pendent studies have shown that active and passive im-
munisation approaches were effective in reducing the
burden of neurofibrillary tangles (NFTs) in the brain,
slowing the progression of the behavioural phenotype or
delaying the onset of motor function decline and weight
loss in mouse models of tau tangle pathology [13-19].
Currently proposed tau immunotherapeutic approaches
are selectively targeting individual phosphorylated tau
(phospho-tau) epitopes such as phospho-Ser396/phospho-
Ser404 [13,14,16], phospho-Thr231/phospho-Ser235 [20]
or phospho-Ser422 [19]. However, tau is a phosphoprotein
that contains 85 potential serine, threonine and tyrosine
phosphorylation sites. Mass spectrometric analysis, com-
bined with sequencing achieved by Edman degradation
and specific antibody reactivity, showed that almost 10
phosphorylation sites on tau can be detected in the nor-
mal brain (Ser46, Thr181, Ser199, Ser202, Thr231, Ser404,
Ser412/Ser413/Thr414 and Ser416), and approximately 45
phosphorylation sites have been found in the AD brain[21,22]. These results suggest that some of the phospho-
sites targeted by proposed immunotherapies are present
in healthy human brains. This finding raises concerns
about the safety of vaccines targeting specific phospho-tau
species. On the other hand, these therapeutic approaches
can selectively target only one or two phospho-sites from
among those forty-five identified in the AD brain. More-
over, the functional significance of the targeted phospho-
sites remains unclear. Likewise, it is unknown whether all
of the pathologic AD phospho-epitopes coexist on the
same tau molecule or whether distinct subspecies of
pathological tau display a variety of different phospho-
codes. On the basis of these limitations, one can assume
that effective immunotherapy against diseased forms of
tau should attack a common denominator of the diseased
tau proteome—the vulnerable area on tau responsible
for oligomerisation, independently from the variety of
its phospho-patterns. Therefore, we have focused our
immunotherapeutic approach on structural determi-
nants essential for pathological tau–tau interactions
with the intent to prevent tau hyperphosphorylation,
oligomerisation and development of neurofibrillary de-
generation in an AD rat model.
Methods
Monoclonal antibodies
AT8 (recognises pSer202/pThr205) was purchased from
Innogenetics (Ghent, Belgium). The phosphorylation-
specific monoclonal antibodies (mAbs) DC209 (recog-
nises pThr231), DC217 (recognises pThr217) and
DC179 (recognises pThr181) were prepared by AXON
Neuroscience SE (Bratislava, Slovak Republic). As a pan-
tau antibody, mAb DC25 was used (AXON Neurosci-
ence SE) [23-29]. DC25 recognises a stretch of seven
amino acid residues (347 to 353, the longest human tau
isoform numbering) in the fourth microtubule-binding
repeat of tau, which is common to all neuronal tau pro-
tein isoforms (human, mouse, rat and other) and recog-
nises all forms of physiological and pathological tau
proteins.
Design and construction of the active vaccine
Tau peptide sequence 294KDNIKHVPGGGS305 was de-
rived from the regulatory domain driving the oligomer-
isation of tau [30]. An extra N-terminal cysteine residue
was added with the aim of obtaining oriented attach-
ment of the peptide on the surface of the keyhole limpet
haemocyanin (KLH) protein. The peptide was coupled
to the KLH carrier (Calbiochem, San Diego, CA, USA)
via the bifunctional cross-linker N-[γ-maleimidobutyry-
loxy]succinimide ester (GMBS). KLH (20 mg) was dis-
solved in conjugation buffer (phosphate-buffered saline
(PBS) with 0.9 M NaCl) to a concentration of 10 mg/ml.
GMBS (2 mg) was dissolved in 50 μl of anhydrous
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1 hour at room temperature (RT). Subsequently, unreacted
GMBS was removed on a 5-ml HiTrap desalting column
(GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) equili-
brated in the conjugation buffer. The peptide (20 mg) was
dissolved in the maleimide-activated KLH solution and the
reaction proceeded for 2 hours at RT. The resulting conju-
gate was dialysed against PBS. The conjugate was aliquoted
and stored at 2°C to 8°C until use.
Transgenic animals
Transgenic rats used in this study expressed human
truncated tau protein in the brain and spinal cord [25].
All transgenic rats used in this study were hemizygous
for the transgene construct. Prior to the experiments, all
animals were housed under standard laboratory condi-
tions with free access to water and food and were kept
under diurnal lighting conditions (12-hour light–dark
cycles with light starting at 7:00 AM). All experiments
on animals were carried out according to institutional
animal care guidelines conforming to international stan-
dards and were approved by the State Veterinary and
Food Committee of the Slovak Republic (Ro-2426/08-
221) and by the Ethics Committee of the Institute of
Neuroimmunology (15 October 2008), Slovak Academy
of Sciences, Bratislava. Efforts were made to minimise
the number of animals utilised.
Vaccine administration
To prepare the tau peptide vaccine, 100 μg of tau pep-
tide conjugate (dissolved in 150 μl of PBS) was mixed at
a 1:1 (vol/vol) ratio with Adju-Phos adjuvant (Brenntag
Biosector, Frederikssund, Denmark) in a final dose vol-
ume of 300 μl. The suspension was mixed by end-over-
end rotation during incubation at 4°C for 6 hours to
allow the peptide conjugate to adsorb onto the adjuvant.
The transgenic rats received five subcutaneous injections
of vaccine (100 μg of peptide-KLH conjugate/dose) start-
ing at 2 months of age, followed by the second injection
3 weeks later and thereafter on a monthly schedule. The
control group of transgenic rats received adjuvant mixed
1:1 with PBS in a final dose volume of 300 μl. Sera were
collected 2 weeks after the last booster dose.
Determination of antibody response to vaccine
Tau peptide (294 to 305), mis-disordered tau (151-391/4R)
and recombinant full-length tau isoform 2N4R were separ-
ately coated onto 96-well plates (SARSTEDT, Nümbrecht,
Germany) at an amount of 250 ng/well. After blocking,
the plates were incubated with the serial dilutions of the
sera (50 μl/well 1:100 to 1:51,200 in PBS, in twofold dilu-
tion steps) for 1 hour at 37°C. Bound serum antibodies
were detected with peroxidase-conjugated secondary anti-
body (goat anti-rat immunoglobulin (Ig), Dako, Glostrup,Denmark) using chromogenic substrate o-phenylenedi-
amine (Sigma-Aldrich, St Louis, MO, USA).
Determination of isotypic profile of vaccine-induced
antibodies
To determine the isotypes of the specific antibodies pro-
duced in response to vaccine, sera from immunised rats
were serially diluted from 1:100 to 1:12,800 in twofold di-
lution steps and tested in duplicates by enzyme-linked im-
munosorbent assay (ELISA) against mis-disordered tau
(151-391/4R). To detect rat IgG1, IgG2a, IgG2b, IgG2c
and IgM isotypes, anti-rat subclass-specific horseradish
peroxidase (HRP)–conjugated secondary antibodies were
diluted 1:5,000 in PBS (Pierce Biotechnology, Rockford,
IL, USA). Antibody isotype levels were compared based
on the half-maximal effective concentration value of the
dilution factor.
Isolation of soluble tau and sarkosyl-insoluble tau
Brain tissue was homogenised in a tenfold weight excess of
ice-cold extraction buffer (20 mM Tris, pH 7.4, 800 mM
NaCl, 1 mM ethylene glycol tetraacetic acid), 1 mM ethyl-
enediaminetetraacetic acid, 0.5% β-mercaptoethanol, 10%
sucrose and 1 mM Na3VO4; 20 mM NaF, supplemented
with cOmplete Protease Inhibitor Cocktail Tablet (Roche
Diagnostics, Indianapolis, IN, USA). After incubation on
ice for 5 minutes, the homogenates were cleared by centri-
fugation at 20,000 g for 20 minutes at 4°C. The superna-
tants were collected, and the total protein concentration
was determined using the Bio-Rad protein assay (Bio-Rad
Laboratories, Hercules, CA, USA). This supernatant (des-
ignated 1S) contained soluble tau fraction. Subsequently,
solid sarkosyl (N-lauroylsarcosine, sodium salt; Sigma-
Aldrich) was added to the 1S supernatant to achieve a 1%
concentration and stirred for 1 hour. Thereafter it was cen-
trifuged at 100,000 g for 1.5 hours at RT. Following centri-
fugation, pellets were gently rinsed with 1 ml of the
extraction buffer and centrifuged at 100,000 g for 20 mi-
nutes at RT. The pellets containing sarkosyl-insoluble tau
fractions were dissolved in SDS-PAGE loading buffer to a
final volume corresponding to the 1/50 of the volume of
1S supernatant used for their preparation. For Western
blot analysis, 6 μl of the sarkosyl-insoluble fraction was
loaded, which corresponds to 30 mg of tissue.
Immunoblot analysis
Samples of sarkosyl-insoluble tau fractions [23] were dis-
solved in 1× SDS sample loading buffer in 1/50 volume
of the soluble fraction and heated at 95°C for 5 minutes.
Each sample in a quantity of 6 μl was then loaded onto
5–20% gradient SDS-polyacrylamide gels and electro-
phoresed in a Tris-glycine-SDS buffer system for 40 mi-
nutes at 25 mA. Proteins were transferred to PVDF
membranes (1 hour at 150 mA in 10 mMN-cyclohexyl-
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the membranes were stained with Ponceau S (Additional
file 1) for verification of loading of an equal amount of
sarkosyl-insoluble proteins and efficiency of electroblot-
ting. Subsequently, the membranes were blocked in 5%
nonfat dry milk in PBS for 1 hour at RT and then incu-
bated for 1 hour with primary (tau-specific) monoclonal
antibodies, followed by three washes with a large volume
of PBS. After washes, HRP-conjugated goat anti-mouse
Ig (Dako) diluted 1:4,000 with PBS was used as a sec-
ondary antibody. Incubation (1 hour at RT) was followed
by washing (three times) with 0.2% Igepal in PBS. The
blots were developed with SuperSignal West Pico
Chemiluminescent Substrate (Pierce Biotechnology), and
the signal was detected using the LAS-3000 Imaging
System (FUJI Photo Film Co, Tokyo, Japan). The signal
intensities were quantified using AIDA Image Analyzer
software (Raytest, Straubenhardt, Germany) and then
statistically evaluated. Foetal tau (prepared as described
in [31]) in the amount of 0.6 μg/lane was used as an in-
ternal standard for quantification.
Immunohistochemistry of rat brain tissue
Transgenic rats were deeply anaesthetised with Zoletil-
xylasine and perfused intracardially using a peristaltic
pump for 2 minutes with PBS. The brain was frozen in li-
quid nitrogen and transferred to dry ice. Sagittal brainstem
sections (10 μm thick) were cut on a Leica CM1850 cryo-
microtome (Leica Biosystems, Buffalo Grove, IL, USA).
The sections were postfixed with 4% paraformaldehyde
(PFA) in PBS, pH 7.2 (4% PFA), for 10 minutes. Tissue
sections were incubated with primary antibodies AT8
(Pierce Endogen), pT212 and pS214 (Invitrogen, Carlsbad,
CA, USA), Tau5 (a gift from Dr Lester I Binder) and HT7
(Pierce/Thermo Scientific, Rockford, IL, USA) overnight
at 4°C. Sections were immunostained using the standard
avidin-biotin-peroxidase method (VECTASTAIN ABC
Kit; Vector Laboratories, Burlingame, CA, USA) with VIP
as chromogen.
Immunohistochemistry of human brain tissue
Human postmortem AD brain tissue (Braak stage VI)
was obtained from the Netherlands Brain Bank in ac-
cordance with local ethical approval and written consent
from the donor or the donor’s next of kin. Ethical ap-
proval was obtained for the analyses carried out using
this tissue (Institute of Neuroimmunology, Slovak Acad-
emy of Sciences, 5/2011).
Tissue sections from human AD brain were treated with
cold (+4°C) 99% formic acid for 1 minute at RT (25°C).
Brain sections were incubated for 20 minutes at RT in
0.01 M of PBS, pH 7.4, containing 0.3% Triton X-100 and
1% H2O2, followed by a 30-minute incubation in the
blocking solution (0.01 M of PBS, containing 0.3% TritonX-100, 1% horse serum), followed by overnight incubation
with sera from transgenic rats immunised with the tau
peptide vaccine (diluted 1:1,000) at 4°C. After washing,
the sections were immunostained using the standard
avidin biotin peroxidase method (ABC Elite Kit; Vector
Laboratories). The reaction product was visualised using
Vector VIP as a chromogen (Vector Laboratories). Sections
were then examined with an Olympus BX51 microscope.
NeuroScale
For testing of sensorimotor functions a multi-test battery
with a novel sensitive scoring system—NeuroScale [32]—
was chosen. Briefly, NeuroScale consists of three variants
of beam walking test (square cross-section of 3 cm ×
3 cm, rectangular cross-section of 4 cm × 2 cm, round
cross-section with diameter of 3.5 cm), a prehensile
traction test and a rapid neuromuscular and neurological
examination. Animal performance was evaluated and
scored according to a predefined rating scale. The max-
imal number of points possible to achieve in the beam
walking and prehensile traction tests was five each. Per-
formance on a simple reflex response was scored with a
maximum of one point, except the hindlimb escape exten-
sion reflex, for which we used a 3-point rating scale.
Statistical analysis
Statistical analysis was carried out using the Prism statis-
tical software package (GraphPad Software, La Jolla, CA,
USA). To compare two groups, the Mann–Whitney U
test or an unpaired t-test was applied. The results are
presented as mean ± standard error of the mean unless
otherwise specified. Differences were considered signifi-
cant at the level of P < 0.05.
Preclinical toxicology and safety pharmacology studies
Studies were conducted at good laboratory practice level
at Harlan Laboratories SA (Correzzana, Italy). Four
separate formulations of AADvac1 vaccine (10, 40 and
160 μg of peptide coupled to KLH formulated with
aluminium hydroxide containing 1.5 mg of aluminium
per dose and 40 μg of peptide coupled to KLH formu-
lated with aluminium hydroxide containing 0.5 mg of
aluminium per dose) were compared to placebo.
Single-dose studies consisted of three separate rat
studies with 14 days or 21 days of postadministration
daily clinical observation. Animals were weighed twice
per week, and food consumption was recorded weekly.
The 14-days studies featured complete haematology,
urinalysis, coagulation and clinical biochemistry panels.
Animals were killed on day 15, organ weights of all in-
ternal organs were measured and histopathological ana-
lysis of all tissues was performed. The 21-days study
featured clinical observation after administration of four
times the intended human clinical dose (160 μg).
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white rabbits. Animals received 9 doses of AADvac1 or
placebo in 3-week intervals over the course of 26 weeks.
Animals were clinically observed twice daily. Food con-
sumption and body weights were recorded weekly. The
study featured complete haematology, urinalysis, coagula-
tion and clinical biochemistry panels. Ophthalmoscopic
examinations were performed at baseline and after 13 and
26 weeks. After the animals were killed, organ weights of
all internal organs were measured and histopathological
analysis of all tissues was performed.
An acute central nervous system (CNS) safety pharma-
cology study was conducted in ICR (CD-1) outbred mice
according to a modified Irwin screen test paradigm. Ani-
mals were subjected to detailed neurological examination
for 24 hours after drug administration. An acute cardiore-
spiratory safety pharmacology study was conducted in
Beagle dogs. The cardiovascular (arterial pressure, heart
rate, cardiac contractility (dP/dtmax), systemic blood flow
and electrocardiography) and respiratory parameters (rate,
tidal volume and minute volume) were recorded and
analysed before and 5, 15, 30, 45 and 60 minutes after pla-
cebo or vaccine administration. Histopathological analysis
was peer-reviewed by AnaPath GmbH, Oberbuchsiten,
Switzerland. Vaccine and placebo for all toxicology and
safety pharmacology studies was provided by Bachem Dis-
tribution Services GmbH, Weil am Rhein, Germany.
Results
Active tau peptide vaccine containing structural
determinant of tau protein essential for its pathological
interaction generates antibodies discriminating between
pathological and physiological tau
In a tandem paper, we report that the monoclonal anti-
body DC8E8 revealed structural determinants of the tau
protein that are important for the pathological tau–tau
interaction [30]. Thus, targeting these interaction do-
mains could lead to the successful treatment of AD and
related tauopathies. The identified tau determinants
served as a lead for the design of an active peptide vac-
cine, which was used in therapeutic efficacy studies in a
transgenic rat model of AD—SHR72 [25]. We prepared
an active vaccine based on the cysteinated tau peptide
C-294KDNIKHVPGGGS305, which contains the struc-
tural determinant 299HVPGGG304 [30]. The peptide was
conjugated via its N-terminus to a carrier (KLH) and
formulated so that a single dose contained 100 μg of the
conjugated peptide.
For this study, transgenic rats expressing human mis-
disordered tau were chosen. We have previously shown
that these transgenic rats developed extensive NFTs and
axonal degeneration in the brain [25,33]. The neurodegen-
eration correlated well with neurobehavioural changes
[32]. Transgenic rats were immunised with five doses ofthe vaccine, starting at 2 months of age, followed by
the second injection 3 weeks later and thereafter on a
monthly schedule. The experiment was concluded when
the animals were 6.5 months of age. At this age, blood
was collected from the heart. The sera were used for
determination of antibody response to the vaccine. Serial
dilutions (1:100 to 1:51,200) of each serum were tested
against the synthetic peptide 294KDNIKHVPGGGS305,
against mis-disordered tau (151-391/4R) and against
physiological tau 2N4R using indirect ELISA. The tau
peptide vaccine induced a robust antibody response in
immunised rats (Figure 1A). No specific antibodies were
observed in rats immunised with adjuvant only. The geo-
metric mean titres (GMTs) of antibodies specific to the
tau peptide (Figure 1A) and to mis-disordered tau reached
high values (21,000 and 15,000, respectively). On the con-
trary, the GMT of antibodies recognising full-length tau
2N4R (4,000) was more than fivefold lower than that recog-
nising the immunogen. Importantly, the analysed antibodies
showed statistically significantly higher binding activity to
the tau peptide and to mis-disordered tau 150-391/4R, than
to physiological tau 2N4R (P = 0.0003 and P = 0.0028,
respectively) (Figure 1B). Vaccination with tau vaccine
carrying DC8E8 epitope induced antibodies preferentially
recognising mis-disordered tau protein, thus discriminating
between pathological and physiological tau.
Antibodies specific to mis-disordered tau induced by
vaccination are predominantly of immunoglobulin
G isotypes
To determine the isotypes of the antibodies produced in
response to the tau vaccine, sera from rats were serially
diluted (1:100 to 1:12,800) and tested against mis-
disordered tau (151-391/4R) using ELISA. Vaccination of
rats with the tau peptide vaccine preferentially induced for-
mation of IgG1 antibody isotypes specific to mis-disordered
tau (151-391/4R) (Figure 1C), indicating a predominant
type 2 helper T cell (Th2) type of immune response. More-
over, the presence of high levels of IgG1 antibodies with
preferential affinity to mis-disordered tau points to the
therapeutic potential of such antibodies. By contrast, the
isotypic profile showed low levels of IgM antibodies, which
are considered to have low affinity to the antigen.
Vaccination significantly reduces tau oligomerisation and
pathological tau phosphorylation
We have previously shown that a transgenic rat model
expressing misfolded truncated tau protein developed
extensive neurofibrillary pathology. The proteomic ana-
lysis of NFTs revealed that insoluble tau consisted of
monomeric truncated tau (about 30 kDa), highly phos-
phorylated forms of truncated tau (30 to 36 kDa), tau
oligomers (above 36 kDa) and full-length tau (above
43 kDa) [25]. Because the AD pathology in transgenic
Figure 1 Antibody response in transgenic rats immunised with tau peptide vaccine determined by enzyme-linked immunosorbent
assay. Tau peptide vaccine induces high antibody levels specific to the tau peptide 294KDNIKHVPGGGS305. No antibody response was observed in
the mice immunised with adjuvant only. Data shown are serial twofold dilutions of animal sera (A). Antibodies elicited by vaccination exhibited
statistically significantly higher binding activity to tau peptide and to mis-disordered tau (151-391/4R) than to full-length tau 2N4R (***P = 0.0003
and **P = 0.0028, respectively) (B). EC50, Half-maximal effective concentration. Vaccine-induced antibodies specific to mis-disordered tau are
prevalently of the immunoglobulin G (IgG) isotype (C). The data shown are means with error bars representing SD.
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impact of treatment on the tau oligomers was analysed.
The brainstems of the treated and untreated transgenic
rats were used for the extraction of sarcosyl-insoluble
pathological tau. Immunisation with tau vaccine induced
significant reduction of the level of highly phosphory-
lated forms of truncated tau (30 to 36 kDa), tau oligo-
mers (above 36 kDa) and full-length tau (above 43 kDa)
revealed by measurement with pan-tau monoclonal anti-
body DC25 (P = 0.0322) (Figure 2A and F). Moreover,
analysis with phospho-dependent monoclonal antibodies
revealed significant reduction of the levels of insoluble
tau species phosphorylated at Thr217 (pThr217, P =
0.0094; Figure 2B and F), pThr231 (DC209, P = 0.0077;
Figure 2C and F), pSer202/pThr205 (AT8, P = 0.0112;
Figure 2D and F) and pThr181 (DC179, P= 0.0100; Figure 2E
and F). These results show that the immunisation
significantly reduced early forms of pathological tau(represented by monomers, dimers and oligomers) and late
forms of pathological tau polymers (represented by paired
helical filaments (PHFs)) as well.
Active vaccination decreased the number of transgenic
rats with fully developed neurofibrillary pathology
For determination of the therapeutic efficacy of the tau
peptide vaccine, we used immunohistochemical methods
to stain NFTs in serial cryosections of rat brains. We
found that several monoclonal antibodies, including
TAU5 (part A in Additional file 2), HT7 (B in Additional
file 2), pT212 (C in Additional file 2) and pS214 (D in
Additional file 2), recognised neurofibrillary degener-
ation in transgenic rat brain. For further quantification,
we selected antibodies recognising pathological tau
phosphorylation, such as pT212 and pS214, and anti-
body AT8, which is recommended as a marker for tau
pathology in human AD [34]. We compared number of
Figure 2 Immunisation with tau peptide vaccine reduced tau oligomers and tau hyperphosphorylation. Western blot analysis with
pan-tau monoclonal antibody DC25 showed reduction in oligomeric tau in the brain of transgenic rats treated with tau peptide vaccine (A). The
monomeric endogenous rat tau proteins run between 43 and 68 kDa marker bands, whereas monomeric transgenic tau comprises multiple
phospho-species between 29 and 43 kDa marker bands. In the vaccine-treated animals, there are only remnants of nonphosphorylated
transgene running just above the 29 kDa marker band. Western blot analysis revealed significant reduction of hyperphosphorylated tau species
phosphorylated at Thr217 (monoclonal antibody (mAb) DC217) (B), pThr231 (mAb DC209) (C), pSer202/pThr205 (mAb AT8) (D) and pThr181
(mAb DC179) (E). (F) The graph represents the quantification and statistical evaluation of the difference between animals treated with vaccine
and those treated with adjuvant only; *P < 0.05, **P < 0.01 . A 6-μl sarkosyl-insoluble fraction was loaded per lane, which corresponds to 30 mg
of tissue. Loading of an equal amount of sarkosyl-insoluble proteins, and the efficiency of electroblotting was verified by staining the membrane
with Ponceau S (Additional file 1).
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in the brainstem. The majority of treated transgenic
rats displayed reduced numbers of NFTs (nNFTs;
AT8, nNFTs <5; pT212, nNFTs <10; pS214 nNFTs <10;
Figure 3A, D and G), whereas the majority of untreated
transgenic rats showed higher numbers of NFTs
(Figure 3B, E and H). Immunostaining with AT8,
pT212 and pS214 showed that immunisation reduced
the number of transgenic rats with extensive neurofib-
rillary degeneration by 55% (AT8, pT212; Figure 3C
and F) or by 77% (pS214; Figure 3I).
Active immunisation improves the sensorimotor functions
of transgenic rats
In order to test the improvement of sensorimotor func-
tions of immunised transgenic rats, we used a battery ofbehavioural tests—NeuroScale [32]. At 6.5 months of age,
transgenic rats treated with tau vaccine were subjected to
behavioural tests with the aim of determining the effect of
immunotherapy. Rats treated with the tau vaccine showed
significantly decreased escape latencies (P = 0.04, Figure 4A)
and reduced number of hindlimb slips (P = 0.045, Figure 4B)
in the beam walking test compared to the transgenic
rats that received adjuvant alone. The immunisation
significantly improved the total NeuroScale score of the
rats treated with tau vaccine compared to the control
treatment group (P = 0.047, Figure 4C).
Vaccination generated rat antibodies that recognised
neurofibrillary degeneration in the Alzheimer’s disease brain
In order to validate the specificity of antibodies generated by
active immunisation, we tested their ability to immunolabel
Figure 3 Active vaccination reduced the number of transgenic rats developing extensive neurofibrillary pathology. Immunostaining
with AT8, pT212 and pS214 shows low numbers of neurofibrillary tangles in the brainstem of treated transgenic rats (A), (D) and (G) compared
with untreated transgenic rats (B), (E) and (H). Immunisation lowered the number of transgenic rats with extensive neurofibrillary degeneration
by 55% (C) and (F) or by 77% (I).
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tative sera obtained from rats immunised with tau peptide
were able to recognise NFTs and neuropil threads in the en-
torhinal cortex of AD brains (Figure 5A through 5C). Serum
from a rat immunised with adjuvant only did not recognise
any neurofibrillary pathology (Figure 5D).
Active tau peptide vaccine displayed a favourable safety
and tolerability profile in all toxicology and safety
pharmacology studies
The vaccine was well-tolerated at all administered dose
levels in all tested species throughout the course of all
studies. No effects of toxicological relevance were de-
tected in clinical observation, haematology, blood bio-
chemistry, coagulation analysis, urinalysis, necropsy,
histopathological analysis, CNS safety pharmacology or
cardiorespiratory safety pharmacology. Measured by
body weight gain, all study groups thrived equally. As
expected of a vaccine containing aluminium hydroxide
as adjuvant, subcutaneous administration induced re-
versible nodules up to 1.5 cm in their largest dimension
at the injection site. The morphological study of the in-
jection sites showed focal/multifocal subcutaneousgranulomatous inflammation with abundant histiocytes
consistent with the histological presentation of an alu-
minium granuloma.
To assess possible negative impacts on the immune sys-
tem, thorough haematological analysis was conducted in
acute and chronic toxicology studies in rats and rabbits,
respectively. The haematology panel featured the following
assessments: erythrocyte count, haemoglobin, haematocrit,
mean corpuscular volume, red-cell volume distribution
width, mean corpuscular haemoglobin, mean corpuscular
haemoglobin concentration, haemoglobin concentration
distribution width, reticulocyte count, reticulocyte matur-
ity index, platelet (thrombocyte) count, total leukocyte
count, differential leukocyte count (neutrophils, lympho-
cytes, monocytes, eosinophils, basophils, large unstained
cells). Both absolute numbers and relative amounts of
white blood cells were assessed. The vaccination did not
induce any toxicologically relevant effect on any of the ob-
served parameters.
Discussion
The neurofibrillary pathology composed of disease-
modified tau protein is the main pathological correlate
Figure 4 Tau vaccine improves sensorimotor functions of
transgenic rats. Tau vaccine–treated transgenic rats showed
decreased escape latency (A) and reduced hindlimb slips
(B) compared to adjuvant-treated controls. Tau vaccine–treated
transgenic rats had significantly lower NeuroScale scores than
adjuvant controls, which reflects an improvement of sensorimotor
functions (C), *P < 0.05.
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and related tauopathies [1,3,35]. Thus, a variety of thera-
peutic approaches targeting the tau misfolding cascadehave been proposed [11,36,37]. Tau immunotherapy rep-
resents an emerging disease-modifying strategy that can
prevent or reduce tau oligomers and/or neurofibrillary
pathology. Several independent studies showed that ei-
ther active or passive immunotherapy can reduce tau
hyperphosphorylation, prevent tau aggregation or clear
tau oligomers and insoluble aggregates [13-16,18,19].
However, until now, no anti-tau immunotherapy has
been reported to enter clinical trials in AD. In this study,
we present preclinical efficacy results of the tau peptide
vaccine, which is the prototype for the first-in-man tau
vaccine that entered phase I of clinical trials in June
2013 under the name AADvac1 (details can be found on
the Clinicaltrials.gov registry homepage under identifiers
NCT01850238 and NCT02031198) with the aim of pro-
tecting tau from its pathological tau–tau interactions.
Previously, we identified the vulnerable, immunologic-
ally distinct structural determinants on pathological tau
that are essential for its misfolding and oligomerisation
[30]. With this knowledge, we developed a tau peptide
vaccine encompassing the structural determinant de-
rived from the mis-disordered second microtubule-
binding repeat domain of tau. With the aim of improving
immune response to the vaccine, the cysteinated 12-mer
tau peptide was conjugated to the carrier protein
(KLH). Previous active immunisation trials with a β-amyloid
vaccine (AN-1792 [38,39]) showed severe adverse ef-
fects induced by a cell-mediated Th1 immune response,
highlighting the importance of safety aspects of vaccine
design. In our tau peptide vaccine, the helper T-cell epi-
topes are derived exclusively from the carrier protein
due to the small size of the adopted tau peptide. More-
over, the vaccine is formulated with an adjuvant that
promotes Th2 immune response [40]. In summary, the
final vaccine formulation contains a B-cell epitope de-
rived from tau and helper T-cell epitopes derived from
KLH in combination with a Th2-promoting adjuvant,
thus inducing a Th2 humoral antibody response directed
against mis-disordered tau.
The tau vaccine elicited a robust and specific antibody
response. Applied vaccine induced generation of high-
affinity antibodies targeting pathological tau in immu-
nised animals. Moreover, the immune response to the
active vaccine was shifted towards the Th2 phenotype,
underlining its safety. Taken together, our results dem-
onstrate a highly favourable safety profile of the pre-
sented tau vaccine, which was confirmed by detailed
toxicology studies.
An extensive review of the literature on the correlation of
AD neuropathological changes with cognitive impairment
clearly showed that the severity of cognitive impairment
correlates best with the burden of neocortical NFTs [3].
Moreover, the number of NFTs correlates with disease dur-
ation, supporting the idea of a progressive accumulation of
Figure 5 Sera from transgenic rats immunised with tau peptide recognised neurofibrillary degeneration in the Alzheimer’s disease
brain. Three representative sera obtained from rats immunised with tau peptide recognised neurofibrillary tangles and neuropil threads in the
entorhinal cortex of Alzheimer’s disease brain (A)-through (C). In contrast, serum from a rat immunised with adjuvant did not recognise any
neurofibrillary pathology (D). Scale bar = 100 μm.
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lated with disease duration in both typical and atypical
cases of AD, suggesting that distribution of tau pathology
in different brain areas determines the specific clinical pic-
ture of dementia [2]. Furthermore, it has been shown that
tau pathology is frequently seen in subcortical nuclei [41]
and that the motor signs predict cognitive and functional
decline, institutionalisation and mortality in AD [42].
We have previously shown that tau pathology is distrib-
uted in several brain areas of tau transgenic rats, including
forebrain and subcortical areas similar to human AD
[23-25]. Similar to AD, the distribution of tau pathology in
the brain of transgenic rats determines the clinical outcome.
We have demonstrated that transgenic rats have neurobe-
havioural impairment as measured by a battery of tests
[32,43]. Interestingly, the active immunisation of transgenic
rats with the tau peptide vaccine was shown to have a
therapeutic effect on several levels. First, the vaccine dis-
played a disease-modifying effect on disease progression
by targeting the main pathological AD hallmarks—tau
oligomers—that correlate well with the clinical outcome. It
reduced early (oligomers) and late (PHFs) manifestations of
tau pathology and thus improved the health status of trans-
genic rats. Second, immunisation led to a significant de-
crease of tau phosphorylation on several AD-related
phospho-sites, such as pThr181, Ser202, pThr205, pThr217
and pThr231. It is important to note that the majority of
other preclinical tau vaccine studies have shown reduction
of tau phosphorylation in transgenic mouse brains, mostly
on those phospho-sites that were part of the originalimmunogen [13,18,19]. In contrast to those studies, our tau
immunotherapy attacks very early stages of tau oligomerisa-
tion that precedes tau hyperphosphorylation, thus removing
the mis-disordered tau substrate for hyperphosphorylation.
This is in line with the notion that tau therapy should not
target just one or two phospho-sites, because of the pro-
nounced heterogeneity of phospho-tau species in the AD
brain that participate in tau oligomerisation.
It has been shown in studies on transgenic mice that tau
active immunisation can improve various neurobeha-
vioural parameters in treated animals. Tau vaccination in-
creased the time the mice were able to stay on the
accelerating rotarod and reduced the number of foot slips
in the traverse beam task [13] or improved short-term
memory in the Y maze [19]. In our study, we tested the ef-
ficacy of the tau peptide vaccine using the NeuroScale—a
battery of behavioural tests featuring a novel scoring sys-
tem for the phenotyping of the transgenic rat model of
tauopathy [32]. Our results clearly show that vaccination
improved the sensorimotor impairment of transgenic rats.
Finally, it is important to note that vaccination elicited
specific rat antibodies that were able to recognise tau
lesions, including NFTs and neuropil threads in the AD
brain. Therefore, it is reasonable to expect that the elic-
ited antibodies will exert the same pattern of therapeutic
activity in AD patients.
Conclusions
In the present study, we have thoroughly charac-
terised a new type of active tau vaccine. On the
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(1) immunogenic—induces a strong antibody response,
(2) specific—targets only one antigenic site on tau,
(3) selective—discriminates between pathological and
physiological tau, (4) safe—helper T-cell epitopes are
derived exclusively from the carrier protein (KLH), and
the immune response is shifted to the Th2 phenotype,
(5) therapeutically effective—reduces pathological tau
phosphorylation and pathological tau oligomers and (6)
improves neurobehavioural parameters. It is important
to highlight that the active tau peptide vaccine AAD-
vac1, based on the tau peptide 294KDNIKHVPGGGS305,
after successfully passing through toxicology and safety
pharmacology studies, has already entered the phase I
clinical trial phase.
Additional files
Additional file 1: The Ponceau S staining of representative
membranes after Western blot transfer of sarkosyl insoluble tau.
Additional file 2: Immunostaining of the transgenic rat brain
demonstrates that NFTs are recognized by different monoclonal
antibodies including TAU5, HT7, pT212 and pS214.
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